艾迪注射液联合化疗治疗晚期非小细胞肺癌40例临床观察

Treatment of 40 cases of late non-small cell lung cancer with Aidi Injection combined with chemotherapies

目的观察艾迪注射液联合盖诺+顺铂化疗与单纯化疗治疗晚期非小细胞肺癌的疗效、不良反应及其对免疫功能的影响。方法将经病理确诊的非小细胞肺癌80例分为两组。对照组40例采用盖诺+顺铂方案化疗,盖诺25mg/m2,d1、8,顺铂30mg,d1～4;治疗组在此基础上加艾迪注射液50mL溶于250mL生理盐水中,连用8～10d。21天为一周期,连用2周期评价疗效。结果毒副反应方面胃肠道反应两组分别为30%和65%,骨髓抑制两组分别为25%和55%,在统计学上有明显的差异性(P<0.05);治疗组免疫功能的改变均低于对照组(P<0.05);治疗组生活质量、KPS评分高于对照组,差异有显著性(P<0.05)。结论艾迪注射液联合化疗治疗晚期非小细胞肺癌,可降低化疗对患者免疫功能的影响及毒副反应,改善患者的生活质量。

Objective To observe the curative effects, adverse reactions and influences on immunity of Aidi Injection combined with chemotherapies of Gainou Injection （Vinorelbine Injection） and Shunbai Injection （Cisplatin, DDP Injection） or chemotherapy alone on late non-small cell lung cancer. Method Eighty cases diagnosed pathologically as non-small cell lung cancer were randomly divided into two groups. The control group （n=40） was treated with chemotherapy plan of Gainuo Injection （25 mg/m^2 d1, 8） combined with Shunbai Injection （30 mg/m^2, d1-4）, and the treatment group was given 50 mL of Aidi Injection （dissolved in 250 mL of normal saline） besides the same treatment as the control group for 8 to 10 days. One cycle of treatment was for 21 days and after 2 cycles the curative effects were evaluated. Result The gastrointestinal reactions in two groups were 30 % and 65 % respectively, and marrow inhibition, 25 % and 55 %. There was a significant statistic difference （P〈0.05）. In the treatment group the immunity change was less than that in the control group （P〈0.05）, and the living quality and KPS sore in the treatment group were higher than those in the control group with a significant difference （P〈0.05）. Conclusion The combination of Aidi Injection with chemotherapies for treating non-small cell lung cancer can reduce the influence and toxic or side effects of chemotherapies on patient＇ s immunity, and improve the living quality.